Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
about
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancerVitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolismAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for the long term treatment of venous thromboembolism in patients with cancerAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesVenous thromboembolism in cancer patients: an underestimated major health problemFixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.Latest medical treatment strategies for venous thromboembolism.Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewImpact of venous thromboembolism and anticoagulation on cancer and cancer survivalVenous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study.The potential benefits of low-molecular-weight heparins in cancer patientsSafety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosisSuppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.Inferior vena cava filters: current best practices.Management of thrombosis in cancer: primary prevention and secondary prophylaxis.Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient.Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin.Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.Evaluation and management of chronic pulmonary thromboembolic disease.Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism.The Role of Tinzaparin in Oncology.
P2860
Q24194904-50B39D48-3759-4860-890B-6F4E514353AEQ24198032-7DADCD2E-D028-48CF-94B4-4476CE6BDB43Q24236620-0A323DE8-DFCC-4AD6-B6D3-FF5588A5B138Q24243286-FCCB6730-7A8D-480B-AD14-A02ACD723CC3Q24633053-086E5B10-3D57-488B-8AED-5F30A7082498Q26852015-39C41625-C5A3-4294-9D40-BFE1E2D70EE6Q33362095-46226C87-D938-4430-A076-838747298CDBQ33375535-706B1D81-881D-40B2-A2D5-130A1723E35CQ33380411-2FA58867-044A-4695-8C64-A07AB82C7276Q33561203-FF5A3D24-CD20-4DAF-8104-D717527835FCQ33685299-8266A101-1AB3-4027-A0D4-2F5085638438Q33698360-C04B403C-A98F-449B-840A-CB50C93AD5CDQ33790616-CF707AA1-9698-439D-9120-0CFF65E3CC72Q33790809-743ADFDA-4C81-4AA8-8CFD-C4B85889CACFQ34462703-0DB3D5C3-F3F7-482B-ABB8-965F6B92E880Q36018537-0354C09F-8AD8-487C-93F7-230D2E38293BQ36062161-55A81570-2070-4214-9559-26D61AC16F64Q36265574-8519BDD0-8B56-4739-A649-277EAB42CCB4Q36951531-8C4342B4-8F3A-4DB1-93F8-9D00C2FB49D5Q37197069-C601824C-FE42-4893-923A-69655B58689BQ37924503-F0AA1FE1-0B94-486E-859A-767C10AE89C6Q38664988-7BE7C02A-CDF1-415A-BA2A-7D0F8BD4A6DEQ38741507-CAF2EA57-CC7F-4DE5-A98E-D38457DDC86DQ46917778-A9765831-82BB-47E2-9FCC-909DD31578A4Q47681124-F06752C5-03F5-4D6F-B1B5-A18CC04F3C50
P2860
Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Low-molecular-weight heparin f ...... sons with oral anticoagulants.
@ast
Low-molecular-weight heparin f ...... sons with oral anticoagulants.
@en
type
label
Low-molecular-weight heparin f ...... sons with oral anticoagulants.
@ast
Low-molecular-weight heparin f ...... sons with oral anticoagulants.
@en
prefLabel
Low-molecular-weight heparin f ...... sons with oral anticoagulants.
@ast
Low-molecular-weight heparin f ...... sons with oral anticoagulants.
@en
P2860
P1476
Low-molecular-weight heparin f ...... isons with oral anticoagulants
@en
P2093
P2860
P304
P356
10.1046/J.1538-7836.2003.00364.X
P577
2003-09-01T00:00:00Z